Viridian Therapeutics, Inc. (VRDN) Earnings Call Transcript & Summary
November 4, 2026
Earnings Call Speaker Segments
Greg Rossino
executiveThanks, operator, and good morning to all of you. We appreciate you being here as we go through Viridian's financial results for the third quarter of 2026 along with recent updates on the business. The press release and the slides for today's call can be found on the investors page of our corporate website at viridiantherapeutics.com. Before we get started, I want to remind everybody that forward-looking statements will be part of today's call and webcast; such statements carry risks and uncertainties that might make actual results differ materially from what has been forecasted. You can find a description of those risks in the forward-looking statement disclaimer contained in the press release and slides issued today, and also in our SEC filings, including our quarterly report on Form 10-Q. Joining me today are Steve Mahoney, our President and Chief Executive Officer; Tony Casciano, our Chief Commercial Officer; and Seth Harmon, our Chief Financial Officer. Sean Wu, our Chief Business Officer, will be with us for Q&A. With that, I'll hand the call over to Steve.
Steve Mahoney
executiveThanks, Greg, and good morning, everyone. We're glad you could join us to review the results from our first quarter of the Lumvoa launch in thyroid eye disease. As we laid out in our earnings release earlier this morning, this has been a very strong beginning, and the Viridian team has once again done an excellent job executing across the board. Lumvoa generated $24.7 million in net product revenue, and as of September 30th, we had more than 100 patients on therapy. That is a very encouraging start to the launch and certainly has exceeded expectations. Although we are only at the beginning of the launch period, we see these outcomes as evidence of Lumvoa's strong product characteristics and of how prepared and effective our whole company has been from the very first day of launch. Before we go into further detail on the Lumvoa launch, I'd like to call attention to the developing Viridian pipeline, which we expect to fuel the coming phase of Viridian's expansion in autoimmune diseases. To start, we remain on schedule to file our BLA for elegrabart during the first quarter of 2027. Ellie is our next-generation subcutaneous anti-IGF-1R. According to what we saw in Phase 3, Ellie could do more to enhance how TED patients experience treatment, and we think it will prompt additional patients to pursue care through at-home self-administration on a schedule as infrequent as once every 8 weeks. We're also eager, later in this quarter, to report first-in-human data for VRDN-008. This candidate, 008, is an FcRn inhibitor with extended half-life, and it stands as one more example of a product candidate built to lessen treatment burden through less frequent dosing while delivering sustained disease control. Strong momentum is likewise underway with our anti-TSHR product candidate, now designated VRDN-292, which we believe could achieve best-in-class status. Later this quarter, we anticipate starting a Phase 1 clinical trial of VRDN-292 in patients with Graves' disease. Taken together, these programs make up Viridian's future, establishing a leading position in TED while extending our portfolio into additional autoimmune diseases. I'll now hand things over to Tony, who will take you through the Lumvoa launch.
Tony Casciano
executiveThanks, Steve, and good morning, everyone. Bringing Lumvoa to TED patients has been deeply rewarding for our team, and I'm proud of how we've begun. I'll briefly revisit the market and Lumvoa's profile, then cover the quarter and what lies ahead. Let's begin with the patients. As a reminder, TED is an autoimmune condition that primarily affects women between 40 and 50 years old who have families, jobs, and active lives. Around the eyes, TED produces inflammation, tissue expansion, and damage. Those effects create disfiguring and debilitating symptoms and shape how patients function daily. In the most severe instances, sight itself can be threatened. TED is likewise a sizable, well-established market where the first approved therapy generates roughly $2 billion in yearly sales, even though it holds only about single-digit penetration across the entire TED market. Prescribers for TED are heavily concentrated: roughly 2,000 core prescribers write over 80% of IGF-1R scripts. Such physicians know how to treat TED, have built referral networks, and are skilled at coordinating with infusion centers. This allows us to serve the market efficiently through a targeted field team. TED is a market that is just starting out. Whenever a TED patient pursues treatment, Lumvoa gets a chance to be selected. That is the role Lumvoa fills. Lumvoa has a strong product profile that we think addresses unmet needs in TED. In our trials, the drug produced substantial improvements in proptosis and diplopia for patients with active and chronic TED. Those gains arrived quickly—meaningful proptosis reductions were seen in as little as 3 weeks. We believe this mix of rapid, substantial, and lasting benefit gives TED patients a compelling option. On top of that, Lumvoa delivers these benefits via a short 12-week course involving only five infusions, letting patients complete treatment fast and get back to their active lives. Early feedback suggests this profile resonates with patients and physicians, and that enthusiasm is already generating meaningful launch momentum. Against that background, let's move on to the quarter. The first quarter of the Lumvoa launch, as Steve mentioned, came in above what we had expected. In our view, this robust beginning speaks to Lumvoa's attractive product profile, to years of groundwork, and to solid execution from the Viridian team. At the time we announced Lumvoa's approval, we laid out the early launch indicators we were tracking: field execution, payer coverage, and demand. Across all three, we are seeing strong progress in these early days of the launch. As we stated at launch, our top initial priority was to quickly engage the core physicians who treat TED and prescribe IGF-1R. That is precisely what we did. Our reps were fully trained and in the field talking to physicians about Lumvoa within 24 hours of approval; we have a highly experienced team with a track record across multiple launches, including buy-and-bill products. The bonds this team forged with core prescribers before approval let us start strong and generate the wide engagement we've achieved with KOLs and prescribers. As we anticipated, the team is performing at a very high level during these early launch days. Market access is another leading priority. We committed to leveraging the foundation built with payers through our preapproval efforts to secure payer coverage quickly after approval. That is precisely what we're doing. During Q3, we finished post-approval presentations with every major payer, covering over 90% of covered lives in the U.S. Our payer coverage progress is substantial, and we remain on track to reach broad coverage for Lumvoa within our projected timeline of 6 to 9 months from launch; we acted swiftly to seek a permanent J-code after approval, and we're happy to report that CMS has assigned one for Lumvoa, effective January 1st, 2027. That's one more illustration of a team that is prepared and understands how to navigate this market. This execution on all fronts, combined with Lumvoa's compelling profile, is producing strong early demand for Lumvoa. Over 100 patients were receiving Lumvoa treatment at quarter's end. To be clear, these are not enrollment forms; they represent more than 100 patients who began treatment with Lumvoa and had received at least one infusion by the close of the quarter. This demand generated $24.7 million in net product revenue during our first launch quarter. We take great pride in this start and in the strong execution against the launch priorities we set out. We also know it remains early, and additional work lies ahead. The Viridian team is operating at full power and focused on extending this momentum. Our launch priorities remain the same: drive awareness, differentiate Lumvoa, and deliver access. As we mentioned when the product was approved, during these first few quarters that work involves connecting with prescribers, helping patients navigate the treatment process, securing coverage, and providing outstanding support through Viridian Cares. Those are our priorities for Q4 and going forward. With prescribers, our efforts center on ongoing education regarding Lumvoa's clinical data and strong profile, along with ensuring Viridian gives them full backing. We have already seen prescribing that is both broad and deep, and we will continue striving to advance both. Our market access group has worked with payers effectively, both prior to and following launch, to move policy coverage forward for Lumvoa and make patient access easier. As we have stated, policy adoption requires time after a product is approved, and payer decision-making schedules frequently vary. The team has made great strides on this front and will continue building from here. When it comes to patients, our patient support services group, Viridian Cares, is still vital to the launch. Viridian Cares has focused on helping treatment get started by assisting patients, physician offices, and infusion centers from the enrollment stage all the way through the treatment journey. Delivering outstanding experiences to every patient and physician stays our priority, along with setting the standard for what they can expect from Viridian's world-class patient services, which depend on our skilled and highly capable patient access liaison team. Overall, it was an excellent first quarter of launch, and the team's execution makes us incredibly proud; even so, we know our work has only just begun, and plenty of TED patients remain whom we can reach. Lumvoa presents a considerable opportunity over the long term, and we are fully committed—100%—to keep delivering for patients. With that, I'll turn things over to Seth.
Seth Harmon
executiveThanks, Tony, and good morning to everyone. This morning's press release contains our complete third quarter results, along with our Q3 10-Q, which was filed with the SEC today, and I'll concentrate on the key points. As noted, Lumvoa brought in $24.7 million of net product revenue during its first quarter on the market; we closed the quarter with slightly more than $955 million in cash, cash equivalents, and marketable securities on our balance sheet. Our financial position is strong enough to fund and carry out our existing business plans through profitability; with that, I'll hand the call back to Steve for his closing remarks.
Steve Mahoney
executiveThank you, Seth. As you can see, the Lumvoa launch is off to a strong start. What adds to the excitement here is the promise of Viridian's pipeline now that it's coming into clearer view. These programs can be folded into the infrastructure we already have, where our execution record is well proven, and we're eager to push them forward as quickly as we can. Let's run briefly through the pipeline highlights. Ellie produced solid results across two pivotal Phase 3 clinical trials in TED, and we remain on schedule to file the BLA during the first quarter of 2027. Our view is that Ellie, given via an autoinjector pen as seldom as once every 8 weeks, could reshape TED treatment by delivering the strong clinical benefit of IGF-1R inhibition to patients so they can self-administer at home. VRDN-292 is our possible best-in-class, half-life extended anti-TSHR candidate, built for infrequent subcutaneous dosing through an autoinjector, and we anticipate beginning the Phase 1 study in Graves' disease patients later this quarter. TSHR is a target offering an exciting new route to helping people who live with Graves' disease and TED. With Lumvoa and Ellie as a foundation, we think Viridian is uniquely positioned to move this new mechanism forward and to lead across the entire spectrum of thyroid autoimmunity. Past TED and Graves', we're eager to share updates later this quarter on our FcRn portfolio, among them first-in-human data for VRDN-008. VRDN-008 has half-life extension and is intended as a possible best-in-class FcRn inhibitor for patients with multiple autoimmune diseases, several of which already carry commercial and clinical validation. We're also still building what comes next, spanning everything from internal discovery efforts to assessing external opportunities; these are genuinely exciting times at Viridian. To close, our early launch results leave us encouraged. More work lies ahead as we execute from a position of strength. My thanks go to our team, the patients, and the physicians involved in the early adoption of Lumvoa; as an organization, we take great pride that Lumvoa is now reaching patients with TED. Operator, please open the line for questions.
Laura Chico
analystMorning, and thanks for taking my question. Congrats on the quarter. I suppose what I wanted to ask about is the gap between when a prescription gets written and when revenue shows up; it felt like, before launch, you were expecting that timeline to run a little longer. Could you speak to the cadence there and how it compares post-launch? What I'm really trying to get at is whether this is a bolus of demand or whether we should expect continued uptake. Thanks so much.
Tony Casciano
executiveThanks for the question, Laura. As we discussed before, we expect the time from enrollment form to infusion to typically run 60 to 90 days, and that was based on what we understood the Tepezza experience to be. In the early days of launch, we anticipated it landing toward the later side. I can say we're pleased with what we've seen so far, but again, it's early in this launch, and we'll need to see it sustained through subsequent quarters. Particularly on your question about bolus, we don't believe we're seeing a bolus here. As a reminder, the TED marketplace doesn't really lend itself to bolus of patients. It's an urgent condition, patients progress rapidly, and again, there was an existing therapy on market prior to our launch, wouldn't anticipate much of a bolus, but again, early quarters, we need to see this play out over subsequent quarters. Thanks for the question.
Laura Chico
analystThank you, Tony.
Faisal Khurshid
analystHi there. Appreciate you taking my question. Regarding those 100 patients on Lumvoa at the close of the quarter, could you give us at least a broad picture of where each stands in their infusion schedule? I'm just trying to get a sense, as we head into the fourth quarter, of how much remaining course there is among those 100 patients and how we should think about de novo demand for the fourth quarter. Thanks.
Tony Casciano
executiveExcellent question. Given the timing of our approval, most of those patients started treatment in the later portion of the quarter.
Faisal Khurshid
analystUnderstood. Many thanks.
Gavin Clark-Gartner
analystHi, everyone. It's really encouraging to see how the launch is going. From what I understand, more than 100 patients have received infusions to date, and by my math the revenue suggests roughly 300 doses were administered. I'm trying to reconcile that with the fact that many patients were treated later in the quarter. Should we be thinking about any stocking effect or other factors when looking at that revenue figure?
Tony Casciano
executiveThat's a very good question. As we've mentioned before, we don't expect much stocking to occur with this launch, largely because this market operates on demand. Once a patient is scheduled for an infusion, infusion centers will place their order for the product. There really isn't much stocking involved. One reason we thought it was important to highlight the more than 100 patient starts in this release was to make it clear that, in our view, the $24.7 million in revenue for the quarter came from patient demand.
Gavin Clark-Gartner
analystUnderstood. Thanks.
Andy Chen
analystHi there. Appreciate you fielding this question. Amgen reported a somewhat softer quarter yesterday because of inventory; no competition was brought up by them. From what you've observed, would you say most of your gains are currently coming at competitors' expense, or are you already picking up early signs that the market could grow past the $2 billion run rate they're at? Thanks.
Tony Casciano
executiveGood question, Andy. To reiterate, our launch approach centers on conversion, as I believe we've said before; we're targeting the 2,000 core prescribers responsible for more than 80% of IGF-1R prescribing. That's our focus. We've also noted in the past that it wouldn't surprise us in the least to see this market expand, given Lumvoa's profile and the way the market is behaving. Again, it's early days. What we're seeing so far has us quite encouraged. We simply need to watch how things develop across the coming quarters, Andy.
Derek Archila
analystMorning, and congratulations on how the launch is going. From what we calculate, having more than 100 patients on therapy suggests Lumvoa took roughly 10% of new starts during the quarter. Would that be a reasonable way to view the early share, and where do you expect share to be in the next 12 months? Thanks.
Tony Casciano
executiveWe'll hold off on saying anything about share, and perhaps just go back to how strong the quarter was and how excited we are about the strong beginning we've made. Once more, I think it's worth repeating that given how well the team in the field executed, we were out early — ahead of approval — booking appointments, talking with customers, and profiling accounts, and we could hit the ground running within 24 hours of approval. That produced quick engagement, quick education of the profile, and in the end what this release shows with more than 100 patients started toward the end of the quarter. Once again, we'll need to watch how this develops over time. The trends so far have us really encouraged.
Alex Thompson
analystHello, and thanks for taking our question. Congratulations again on the quarter. Perhaps I could ask something more specific about the exit velocity from the quarter. I suppose what I want to know is whether you think what you're seeing can be sustained from here, and then as the J-code takes effect in January, how might that affect the trajectory? Thanks.
Tony Casciano
executiveThanks for the question. Look, the results so far have us really excited. We're excited about how we began the quarter, and we're excited about how we finished it. I believe someone already raised the question about a bolus. We don't see that happening in this particular market; getting a full read on how strong this launch really is will require some time. What we can speak to is the picture so far, and it has all of us enthusiastic. Our view was that Lumvoa held substantial promise in this market down the road. Today's numbers and the strides we made during the quarter bear out that enthusiasm, though once more, we'll have to watch how things unfold across the coming quarters. Thank you for asking.
Thomas Smith
analystHey, everyone. Good morning. Congratulations on what was a truly outstanding launch quarter, and thank you for fielding our questions. Would you mind putting a bit more detail behind the payer coverage progress? As of now, where do you stand on covered lives with unrestricted access, and where do you see that heading over the coming 6 months, and what effect do you expect that to have on the net revenue figure going forward? Thanks very much.
Tony Casciano
executiveThat's a great question. The work our market access team has put in is something we're genuinely proud of. It was enabled, again, by being ready early, by understanding this market, and by staying out ahead of approval through the preapproval information exchange. I believe we mentioned that we had reached the majority of covered lives before approval, and then we could reengage quickly after approval, with over 90% of covered lives represented in our post-approval meetings. I'm glad to report that by the close of the third quarter, as we exited September, we had already reached 30% of covered lives with a policy in place for Lumvoa, and the team keeps making headway through the fourth quarter. We can reaffirm today that we expect to be at critical mass, or broad coverage, by 6 to 9 months, and we are well on our way to hitting that mark.
Gregory Renza
analystHey there, good morning everyone. Congratulations on a solid quarter and the progress you've made, and I appreciate you taking my question. So, when you discuss the Lumvoa launch, which may be beating both your own and others' expectations, what are you learning, and how might that performance and execution influence the progress in the filing for elegrabart and then the subQ? Is it helping shape not only the timing but also the approach for bringing that asset forward ahead of FDA? Thanks very much.
Tony Casciano
executiveGreat question. I can speak to the execution and what we're observing; as an organization we were in a really unique spot with this opportunity, given that we had an exceptionally strong product profile. We had highly talented staff here as we built out not only the commercial side but the organization overall, along with a very focused, straightforward conversion plan at launch. Whenever those three elements are present — a compelling product profile, the right people in place, executing well against a clear strategy — good outcomes tend to follow, and that is precisely what we witnessed this quarter. The truly encouraging part is that this is highly repeatable with Ellie. Once again we find ourselves with a very strong product profile with Ellie as that is taking shape. Naturally, we still need to secure that approval, but once it comes, the same team now in place, the infrastructure we established to launch Lumvoa is the very infrastructure we'll use to launch Ellie. We believe this can be repeated.
Lisa Walter
analystThanks for taking our question, and congratulations on the quarter. Could you help us understand how patient start forms are converting into patients on therapy? Can you tell us how many patients have gotten their second infusion? Any detail on this would be useful. Thanks very much.
Tony Casciano
executiveThat's a fair question. When we look at performance during the quarter, with more than 100 patients beginning therapy, again, as was mentioned earlier, most of those patients were starting treatment near the end of the quarter. Most of those patients are at an early stage of their treatment journey with us. Sorry, was there another part to your question?
Lisa Walter
analystI'd like to understand how patient start forms are converting into the count of patients beginning therapy.
Tony Casciano
executiveThat's a good question. Here as well, what we're seeing makes us quite happy. That is yet another item that will need to play out over time before we reach any firm conclusions. Thank you.
Joseph Thome
analystHi there. Good morning, and I appreciate you taking my question, and congrats on the progress. Out of those 2,000 core prescribers, roughly what portion make up the 100 patients currently on therapy, and beyond that, where are the prescription start forms you're seeing originate from? Is it kind of a collective group of core prescribers giving it to several patients, or are you seeing broad uptake? And maybe beyond that, what percentage of those 2,000 core prescribers have signaled an intent to use Lumvoa, perhaps in the near term? Thank you.
Tony Casciano
executiveGreat question. Just as a reminder, our focus is on the 2,000 core prescribers since they account for over 80% of all IGF-1R prescriptions. Our approach centers on conversion. Based on prior IGF-1R use, you'd expect the bulk of our utilization to come from the 2,000 physicians we're targeting. We won't go as far as providing precise percentages, but it's fair to say the depth and breadth we're observing continue to please us. This isn't merely an early trial; we're already seeing some initial signs of adoption. Making sure those trials deliver really strong, positive first experiences—enabled through the support of Viridian and Viridian Cares—will be essential for us moving forward, and that ultimately carries over into wider adoption. We're pleased with the breadth and depth we've observed up to this point, though as noted, we'll need to watch how that unfolds across the quarters ahead.
Douglas Tsao
analystHello, and good morning. Thank you for taking our questions. I suppose, as a follow-up to that previous one, regarding prescribers, I am simply wondering: do you generally observe prescribers first trying the product on a few patients, or have there been cases where clinicians—perhaps already acquainted with the drug through clinical trial experience, or simply enthusiastic about the profile—have essentially switched their entire TED patient volume over to Lumvoa in one go? Thanks.
Tony Casciano
executiveThat is a good question. To restate, what we are seeing satisfies us in terms of both breadth and depth. We observe a little of each. As for the percentages, we will not discuss those on this call. Again, we are pleased with what we are seeing on that front as well. I do not want to sound like a broken record, but this needs time to play out. It is only one quarter.
Douglas Tsao
analystSo I suppose, just to make sure I understand, you're observing a mix of things — a bit of experimentation, but also some doctors who appear to be making the switch quite aggressively. Would that be accurate?
Tony Casciano
executiveYes, that's completely accurate.
Douglas Tsao
analystGreat, thank you very much.
Rami Katkhuda
analystHi everyone, and congratulations on a solid launch. I appreciate you fielding my questions too. I realize it's still early, but could you speak to how the prescribing mix looks across physician specialties, and how Lumvoa usage splits between active and chronic TED patients?
Tony Casciano
executiveLet's perhaps handle the second part first. As we've mentioned before, from what we understand of this market, about 80% of patients who start an IGF-1R therapy are active patients, while the remaining 20% are chronic. Our approach centers on conversion — we're concentrating on the 2,000 core prescribers responsible for 80% of current IGF-1R use. Over time, we'd expect the blend to look much like it has in the past. And as I mentioned before, I wouldn't be taken aback in the least if the market grew somewhat, simply given how strong the Lumvoa profile is. What we're seeing pleases us. The first results have been encouraging. That makes us quite confident about Lumvoa's potential over the long run, though it's too soon to say anything conclusive.
Michael Yee
analystHi, everyone. Great. About the fourth quarter—and thanks for acknowledging the strong launch you're having—should we be looking for an acceleration in Q4, meaning more than 100-something patients added during that quarter, or should we also build in some seasonality that might influence how people pace themselves when coming in and thus schedule things for the first quarter? Could you take us through how we should be thinking about that for modeling purposes regarding patient adds in Q4? Then, if I can get a bonus question by bringing up the pipeline, on 008, where some data is coming, could you calibrate what we should expect for either IgG reductions or how deep or fast those IgG reductions are, and how we ought to compare that with others when considering the profile? Thank you.
Tony Casciano
executiveYeah. Thanks, Michael. Great question. Regarding Q4, we won't provide formal guidance, though it's fair to say that since the majority of those patients—more than 100—began treatment near the close of the quarter, we'll enter Q4 with them already on therapy. We're still at an early stage of this launch, and we'd expect some growth as we move into the next quarter. As for how much growth, we'll need to observe more as the launch progresses before we can have any real conviction about the rate. Again, we're genuinely pleased with what we're seeing, happy with how we finished the quarter, and we'd anticipate a solid fourth quarter as well.
Steve Mahoney
executiveRegarding the 008 question, Mike — yeah, I think what we're after is what you'd expect in terms of where the IgG reduction lands relative to the thresholds that have been fairly well-established by some of the other FcRn programs; we'll be watching for albumin sparing, we'll be watching for dosing frequency, and so we know the profile we'd like to see, and now we just need to see that play out. As stated, we expect to be able to disclose that later this quarter.
Rich Law
analystHi folks, and congratulations on the strong start. Could you walk us through how that flexible payment program operates with the infusion center while you're awaiting activation of the permanent J-code, and what the payment terms are? Also, how is revenue recognized at present versus when you actually get paid, which sometimes happens later? Any detail on this would be terrific, including how much of Lumvoa use so far is being utilized through this program. Thanks.
Tony Casciano
executiveGood question; revenue gets recognized once the specialty distributors receive it. As you said with the J-code, we're quite excited about how well the team executed within a pretty short window. Remember, we got approved at the end of June and needed to submit that application on or around July 1st to make that window. We did so, we made the window, and we were very pleased to get confirmation from CMS that a permanent J-code is in place, effective January 1st of 2027. That's another case of the team grasping this market, understanding its mechanics, and truly performing at a very high level to deliver it not only for us, but for our customers and patients too. Fairly simple. I wouldn't describe it as a payment plan; payment terms is what I'd call it. We haven't disclosed precisely how it looks and probably won't, we'll stop short of that. While we're navigating the J-code period, which can cause some cash flow challenges for infusion centers, we did offer some relief through extended payment terms, which you'd notice in the accounts receivable.
Rich Law
analystOf those 100 patients you brought up, what number are making use of this flexible payment option?
Tony Casciano
executiveThanks for asking. That's a level of detail we won't be providing. Thank you.
Rich Law
analystAll right, thank you.
Serge Belanger
analystGood morning, and congratulations on a solid beginning. It sounds as though you've achieved meaningful momentum already when it comes to locking down payer coverage. I'm wondering whether you still anticipate that coverage will be at parity with Tepezza, and might there be any distinctions when it comes to use in the chronic segment or with retreatments? Thanks.
Tony Casciano
executiveThat's a great question. I appreciate you acknowledging the progress; so 30% of covered lives now have a policy in place for Lumvoa, and that's at parity in nearly all of those instances. I'd simply restate that our team keeps making solid headway, and we remain firmly on track toward the goal we've set of achieving broad coverage by the 6 to 9-month mark. I'd also add, just so it's clear, that as these policies go live, there are additional mechanisms and avenues for getting PAs approved via the medical exception process, and that's exactly where the strength of our patient service team and our patient access liaisons really shines. We never abandon a patient simply because their insurance plan lacks coverage. There are mechanisms and avenues for accomplishing that, and we observe it happening routinely; it's also worth pointing out that many of these plans, while they review the products as they work through establishing a policy, have interim plans in place. There are avenues. I didn't want to give the impression that 70% of patients lack access — that simply isn't accurate. Still, our goal is, again, to reach broad coverage so we can make things as easy as possible for patients, physicians, and infusion centers by the 6 to 9-month mark. The other question concerned whether we expect any variations across plans. Well, that's certainly possible. We have confidence in how strong the profile of Lumvoa is. It's landing well with payers. That isn't our strategy, though. Ours is a strategy of parity; we believe the strength of this drug lies in the profile, and parity access allows us to compete and win with the physician as they make selections for their patients.
Lachlan Hanbury-Brown
analystThank you. I'll add my congratulations as well. I think before launch, you mentioned that patient start forms would be one of the metrics you'd provide. Obviously, more than 100 patients on therapy is an impressive figure, but I'm wondering whether you can give us some color on the count of patient start forms, including those who haven't yet been treated?
Tony Casciano
executiveThanks for the question. I believe we had indicated that we would provide color on each of the launch priorities; enrollment forms would certainly be a reasonable metric. What I think shifted our thinking is how strong the quarter was from a revenue standpoint; so, $24.7 million in net revenues, we believe, speaks for itself; we added patient starts just to ensure people understood that this was demand-driven rather than inventory-driven. I'll stop there for now; going forward, we will likely share net revenues, and then again, considering across those launch priorities, what we think gives the most color on the strength of the launch at that point in time.
Steve Mahoney
executiveThanks. Good morning, everyone — appreciate you being here. Clearly we’ve gotten off to a strong beginning. There’s still a lot of time ahead, but what we’re seeing has us genuinely optimistic. Many thanks, and we’re eager to speak with you again before long.
Operator
operatorThis concludes today's call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Viridian Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Viridian Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Viridian Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.